We conducted a prospective cohort study to examine the associations of 21 gastrointestinal diseases with the risk of incident venous thromboembolism (VTE). The study included 485 936 UK Biobank participants free of baseline VTE. The gastrointestinal diseases were defined by the International Classification of Disease (ICD)-9 and 10 codes with data from the nationwide inpatient data set, the primary

For our initial systematic review of drug-induced thrombotic microangiopathy (DITMA) in 2015,1 we adapted our previous literature search strategy for identification of articles reporting drug-induced thrombocytopenia (DITP) to identify articles reporting patients with DITMA (Table S1). Our criteria for evaluating reports of DITMA to determine levels of evidence for a causal association of the drugs

CONFLICT OF INTEREST STATEMENT Nicholas J. Short has served as consultant for Pfizer Inc., GSK, NKARTA, and Sanofi, reports receiving research grants from Takeda Oncology, Astellas Pharma Inc., Xencor, Stemline Therapeutics, and NextCure, and has received honoraria from Novartis, Amgen, Takeda Oncology, Astellas Pharma Inc., Sanofi, and BeiGene. Fadi G. Haddad reports no relevant conflicts of interest

Desai SH, Spinner MA, David K, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. 2023; 98(3): 464-471. doi:10.1002/ajh.26827 In the published version of the article, the author name, Siddharth Iyenger was incorrect. It should be Siddharth Iyengar.

An 18-year-old male patient presented to clinic with an episode of self-inflicted injury. Routine laboratory evaluation with complete blood count demonstrated severe leukopenia to 0.9 × 109/L (0.1 × 109/L neutrophils, 0.3 × 109/L lymphocytes) with normal levels of hemoglobin (141 g/L) and platelets (238 × 109/L). Lymphocyte enumeration demonstrated that B-cells accounted for 1.8% of total leukocytes

While the use of chimeric antigen receptor-T (CAR-T) therapy for T-cell malignancies is in the early stage of clinical trials, it exhibits substantial potential to offer long-term remission for patients with refractory/relapsed (R/R) T-cell malignancies. In our phase I/II clinical trials, 65 pediatric and adult patients with R/R T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma (T-ALL/LBL)

POEMS syndrome is a life-threatening condition due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder, sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume

Systemic mastocytosis (SM) in adults almost always involves the bone marrow (BM) and less frequently, the skin and other organs, including the liver, spleen, and bones.1 The extent of neoplastic mast cell (MC) proliferation (i.e., MC burden), MC-associated organopathy, and co-occurrence of an associated myeloid neoplasm (AMN) determine disease severity and allow subclassification into indolent SM (ISM)

Pearson marrow pancreas syndrome (PS) is a multisystem bone marrow failure (BMF) disorder caused by deletions in mitochondrial DNA (mtDNA). Infant-onset transfusion-dependent pancytopenia, immune defects, and metabolic crises result in early mortality. However, PS often goes undiagnosed, and its rarity, comorbidities, and occasional spontaneous hematologic improvement deter timely consideration of

Myelodysplastic neoplasms (MDS) are heterogeneous clonal hematopoietic neoplasms with a high risk of evolution into acute myeloid leukemia.1 Given the highly variable clinical courses of MDS, the importance of risk stratification for distinguishing high-risk patients has been underscored.2 Currently, the most widely used survival prediction models are the International Prognostic Scoring System (IPSS)

CD19 directed CAR T-cell therapy is used to treat relapsed/refractory B-cell acute lymphoblastic leukemia. The role of the pre-CAR bone marrow (BM) stromal microenvironment in determining response to CAR T-cell therapy has been understudied. We performed whole transcriptome analysis, reticulin fibrosis assessment and CD3 T-cell infiltration on BM core biopsies from pre- and post-CAR timepoints for

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent thrombosis and/or recurrent fetal loss. APS can be primary or secondary to autoimmune disorders such as systemic lupus erythematosus (SLE). It is unique from other thrombophilic disorders in that it predisposes patients to not only venous but also arterial thrombosis through endothelial cell damage and activation

Zhou et al. recently published a prognostic model for patients with chronic myelomonocytic leukemia (CMML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) in this journal.1 This score consisted of five items: Age, Blasts, Leukocytes, Anemia, and chronic Graft vs Host Disease (ABLAG). The strongest predictor in this score was the absence of chronic Graft vs Host Disease (cGvHD)

CONFLICT OF INTEREST STATEMENT Mrinal M Patnaik has received research funding from StemLine Pharmaceuticals, Kura Oncology, and Epigenetix. He has served on the advisory board for CTI pharmaceuticals.

Myelodysplastic neoplasms (MDS) with ring sideroblasts represent about 30% of all MDS patients and are characterized by severe anemia, transfusion dependence, and limited response to erythropoiesis stimulating agents (ESAs). Most patients harbor a somatic mutation of Splicing Factor 3B1 (SF3B1),1 whose presence identifies a distinct entity in the fifth edition of the WHO classification of myeloid neoplasms

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with acute leukemia. Despite this, studies have shown that only a minority of patients ultimately proceed to allo-HCT. The primary objective of this prospective, observational study was to identify the rate of allo-HCT in patients for whom it was recommended, and reasons why patients deemed appropriate

Sickle cell disease (SCD) is a severe, multisystemic hematological disorder that impacts nearly every major organ in adults. The current approved treatments for SCD directly target mutant hemoglobin or address downstream disease pathology. Several compounds targeting reduction of 2,3-DPG by activation of Pyruvate Kinase-R are currently being evaluated in SCD patients. In this study, we genetically

In the recently published International Consensus Classification (ICC) and the fifth edition of the World Health Organization classification on myeloid neoplasms,1, 2 the importance of TP53 mutation in disease pathogenesis and prognosis is recognized. The ICC goes a step further in recognizing acute myeloid leukemia (AML) with mutated TP53 as a separate distinct entity given that TP53 mutations are

With the availability of effective targeted agents, significant changes have occurred in the management of patients with acute myeloid leukemia (AML) over the past several years, particularly for those considered unfit for intensive chemotherapy. While testing for measurable residual disease (MRD) is now routinely performed in patients treated with intensive chemotherapy to refine prognosis and, possibly

Fludarabine/cyclophosphamide (Flu/Cy) is established for lymphodepletion (LD) prior to standard-of-care CAR T-cell therapy for lymphoma. There is ongoing need to test alternative LD regimens to preserve efficacy, improve safety, and address challenges including the recent national fludarabine shortage. We retrospectively evaluated outcomes among patients with relapsed/refractory aggressive B-cell lymphoma

CD19 chimeric antigen receptor (CAR) T-cells therapy has shown remarkable therapeutic effect in treating relapsed and refractory B acute lymphoblastic leukemia (r/r B-ALL). However, approximately 50% of patients experience relapse within a year due to limited CAR T-cell persistence or CD19 antigen loss.1, 2 Dual-targeting approaches have demonstrated impressive antitumor activity.3 And it has been

Marginal zone lymphoma (MZL) is an indolent type of non-Hodgkin lymphoma that develops through pathological B cell receptor signaling. Orelabrutinib, a new-generation oral small molecule Bruton's tyrosine kinase inhibitor, was evaluated in relapsed/refractory (r/r) MZL patients. Previously treated r/r MZL patients received orelabrutinib 150 mg once daily in a phase 2, multicenter, single-arm study

D-dimer (DD) and ultrasonography (US) are part of the diagnostic workup for lower-extremity deep vein thrombosis (DVT). Recent studies have shown that adjusting DD level cut-offs by age or clinical pre-test probability (PTP) decreases the use of US. We compared diagnostic accuracy of PTP-adjusted DD and age-adjusted DD in 3883 patients (F: 61.1%; age: 65.3 ± 16.8 y) referred to our unit for clinically

The peripheral blood count and blood film can be important in the diagnosis of infectious diseases, particularly when interpreted in the light of the clinical features, geographic setting, and travel history. The observation of atypical reactive lymphocytes is, of course, of crucial importance in the diagnosis of infectious mononucleosis and other viral infections while neutrophilia with reactive changes

Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP-CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. However, recent reports of several such cases has raised concern. To estimate the risk of AP/BP among TD-eligible patients, we conducted TFR-PRO, a cohort retro-prospective study: 870 CP-CML

Multiple myeloma (MM) is the second most common hematologic malignancy diagnosed in adults in the United States (U.S.). Current reports suggest that approximately 5%–7% of all MM patients develop a second primary malignancy (SPM) at some point during their disease course.1 As novel MM therapies translate into improved long-term outcomes, it is conceivable that extended survival will lead to more time

Castleman disease (CD) is a rare and heterogeneous lymphoproliferative disorder with shared lymph node (LN) histology.1 While multicentric CD (MCD) involves multiple enlarged LNs, systemic inflammation, and multi-organ failure, unicentric CD (UCD) involves a single enlarged LN or region of LNs and few to no symptoms.1 Though compressive symptoms are the best-described clinical manifestation of UCD

CONFLICT OF INTEREST STATEMENT Stefan N. Constantinescu is a co-founder of MyeloPro Diagnostics and Research GmbH, Vienna.

Patients with chronic lymphocytic leukemia (CLL) are at increased risk of developing non-hematologic malignancies.1 Definitive or adjuvant radiation therapy is often a critical component of management for localized solid organ cancers. With the advent of novel agents for CLL, such as bruton tyrosine kinase inhibitors (BTKi) and the BCL-2 inhibitor venetoclax, patients with CLL often receive continuous

Sickle cell disease (SCD) is a genetic hemoglobinopathy leading to chronic hemolysis punctuated by vaso-occlusive episodes and responsible for chronic organ damages.1 While the association between SCD and some autoimmune diseases (AIDs) has been reported, the diagnosis of AIDs in this context is often described as difficult and delayed, due to similarities in clinical manifestations of both conditions

Platelet transfusion effectiveness is measured by the corrected count increment (CCI), which is the difference between posttransfusion and pretransfusion platelet counts, corrected for body surface area and platelet dose.1 The CCI can be determined at any time posttransfusion but is usually measured after either one or 24 h. Platelet refractoriness is a consistently poor CCI and is usually defined

Our knowledge of genetic aberrations, that is, variants and copy number variations (CNVs), associated with mantle cell lymphoma (MCL) relapse remains limited. A cohort of 25 patients with MCL at diagnosis and the first relapse after the failure of standard immunochemotherapy was analyzed using whole-exome sequencing. The most frequent variants at diagnosis and at relapse comprised six genes: TP53,

Marginal zone lymphomas (MZL) are collectively the second most common type of indolent lymphoma.

A 27-year-old man, under the care of the dermatology service with a 7-year history of extensive recurrent viral warts on his hands, eyelids, and lips, subsequently developed left-leg lymphedema with associated cellulitic episodes. An inherited immunodeficiency syndrome was considered. His full blood count showed hemoglobin concentration 134 g/L, white cell count 4.36 × 109/L, neutrophils 3.15 × 109/L

Sickle cell disease (SCD) remains prevalent because heterozygous carriers (HbAS) are partially resistant to Plasmodium falciparum malaria. Sickle hemoglobin (HbS) polymerization in low and intermediate oxygen (O2) conditions is the main driver of HbAS-driven resistance to P. falciparum malaria. However, epidemiological studies have reported mixed malaria morbidity and mortality outcomes in individuals

CONFLICT OF INTEREST STATEMENT M.K. has received funding as an advisor/consultant from the following sources: AbbVie, Ionis Pharmaceuticals, Protagonist Therapeutics, Incyte, and MorphoSys. R.H. received research grant funding through his institution from the following sources: Citi BioPharma Corp, Curis, Inc., Dexcel Pharma Technologies Ltd. Genentech, Kartos Therapeutics, Karyopharm Therapeutics

Acute graft versus host disease (aGvHD) is a severe complication that arises in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and remains the primary cause of nonrelapse mortality (NRM). The MAGIC algorithm probability (MAP) has been proposed to identify patients at intermediate and high risk of developing aGvHD. The levels of suppression of tumorigenicity 2 (ST2)

CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest.

Patients with chronic myeloid leukemia (CML) and T315I mutation generally have a poor prognosis. Their outcome in the post-ponatinib era remains unclear. We reviewed patients with CML in chronic (CP) or accelerated phase (AP) who developed a T315I mutation between March 15, 2004, and July 26, 2022. Patients were divided into CP, AP, or blastic phase (BP) at the time of mutation detection. Overall survival

Herpes zoster reactivation (VZR), commonly known as shingles, can lead to postherpetic neuralgia and other more serious complications. VZR risk increases with age and other causes of immunosuppression including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) and lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL).1 We have previously shown that patients with CLL or LPL can

Chronic graft-versus-host disease (cGvHD) remains the most important long-term complication of allogeneic hematopoietic cell transplantation (allo-HCT), but the field has seen significant changes in the last decade. Remarkable advances in the understanding of the biological pathways of cGvHD, lead to the development of targeted therapy with novel drugs thereby minimizing the exposure to harmful corticosteroids